Jürgen Wichmann

Roche (Switzerland) — Switzerland

Neuroscience · Life Sciences

27h-index2.3kcitations79works0.02yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Neuroscience and Neuropharmacology Research(27), Receptor Mechanisms and Signaling(24), Melanoma and MAPK Pathways(23), Computational Drug Discovery Methods(17), Neuropeptides and Animal Physiology(16)

Publications79 total

Mosperafenib, a Novel Paradox-Breaker BRAF Inhibitor with Potent Preclinical Activity in BRAF-Mutated Colorectal Cancer
Molecular Cancer Therapeutics·2025
Abstract 5606: The novel brain-penetrant paradox breaker BRAF inhibitor RG6344 manifests exceptional activity in BRAF mutant colorectal cancers
Cancer Research·2025
Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Table from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Preclinical Characterization of a Next-Generation Brain Permeable, Paradox Breaker BRAF Inhibitor
2023Open Access
Supplementary Data from Activity and Resistance of a Brain-Permeable Paradox Breaker BRAF Inhibitor in Melanoma Brain Metastasis
2023Open Access
page 1 of 4Next →

Frequent Co-authors

Vincent Mutel(18), Geo Adam(12), Frédéric Knoflach(11), Thomas J. Woltering(10), Eric Prinssen(8), Lutz F. Tietze(8), Sabine Kolczewski(7), Eric Vieira(7), Heinz Stadler(7), Theresa M. Ballard(6), François Jenck(6), Jörg Huwyler(6), Silvia Gatti(5), Richard H. Porter(4), Will Spooren(4), Bernd Büttelmann(4), Pari Malherbe(4), James N.C. Kew(4), John A. Kemp(4), James R. Martin(4)